Incretins for Type 2 Diabetes

Area of Science:

• Endocrinology and Metabolism
• Pharmacology
• Public Health

Background:

• Type 2 diabetes (T2D) presents a significant and escalating global health concern, projected to increase healthcare expenditures due to associated morbidity and mortality.
• T2D pathogenesis involves insulin resistance and impaired pancreatic insulin secretion, potentially influenced by glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).

Purpose of the Study:

• To review the advancements and efficacy of incretin-based therapies in managing type 2 diabetes.
• To highlight the evolution of incretin-based treatments from early formulations to dual receptor agonists.
• To discuss the benefits, side effects, and future directions for optimizing incretin therapy in T2D.

Main Methods:

• Review of literature on incretin-based therapies for type 2 diabetes.
• Analysis of clinical trial data on efficacy, weight management, and cardiovascular risk reduction.
• Examination of adverse event profiles and mitigation strategies.

Main Results:

• Incretin-based therapies, including injectable and oral formulations, have shown significant glycemic-lowering benefits and weight reduction in T2D patients.
• Dual GLP-1/GIP receptor agonists represent a major advancement, offering improved glycemic control and cardiovascular risk reduction in high-risk populations.
• Gastrointestinal issues are the most common adverse effects, manageable through dose titration and patient education.

Conclusions:

• Incretin-based therapies are crucial for T2D management, offering substantial benefits in glycemic control and weight loss.
• Dual agonists and evolving formulations enhance treatment efficacy and patient outcomes.
• Continued research into dosing, combinations, and accessibility is vital for maximizing the long-term impact of these therapies.